Lipocine Inc. (LPCN:NASDAQ) closed at $1.60 on October 21, 2026, down 1.23% on the day. The stock trades 87.1% below its 52-week high of $12.37 and 14.3% above its 52-week low of $1.40. Over the past year, it lost 43.1%. Lipocine Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since October 21, 2025, LPCN closed higher on 119 days (47%). Its best day was December 31, 2025 (+22.22%) and its worst was April 2, 2026 (-77.84%). The stock moved 10% or more in a single session 19 times. It opened at least 5% above the previous day's high 2 times.
Lipocine Inc., a specialty pharmaceutical company, develops pharmaceutical products using its oral drug delivery technology in the areas of men's and women's health. The company offers a portfolio of proprietary product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is LPCN 1021, an oral testosterone replacement therapy designed for twice-a-day dosing that has completed Phase 3 testing. The company's pipeline candidates also include LPCN 1111, a next generation oral testosterone therapy product with once daily dosing that is in Phase 2 testing; and LPCN 1107, which has completed Phase 2 testing for the prevention of recurrent preterm birth. Lipocine Inc. is headquartered in Salt Lake City, Utah.
Find more stocks like LPCN with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.